People · Operator
Named in public records as an officer, director or promoter · active 2014–2026 · Other Health Care, Other Technology, Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Mirabilis Medica, Inc. | — | Other Health Care | Series A | $33.7M | $8.7M | 2015 |
| Health Fidelity, Inc. | — | Other Technology | Series B | $33.4M | $586.7M | 2014 |
| Great Lakes Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $11.2M | $347.5M | 2014 |
| MultiValent Biotherapies, Inc. | — | Biotechnology | Series A | $10.0M | $25.2M | 2026 |
Fred Schwarzer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Fred Schwarzer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gino DiSciullo | 2 | 4 |
| Dinesh Patel | 1 | 13 |
| Josh Baltzell | 1 | 7 |
| Jan Garfinkle | 1 | 7 |
| Kevin Fong | 1 | 6 |
| David Auth | 1 | 5 |
| Stephen Snowdy | 1 | 4 |
| Jens Quistgaard | 1 | 3 |
| John Neis | 1 | 3 |
| Mike Connolly | 1 | 3 |
| Michael Lau | 1 | 3 |
| Jeff Stein | 1 | 2 |
| Bruce Keyt | 1 | 2 |
| John Kuzmishin | 1 | 2 |
| Wayne Poll | 1 | 2 |
| C. Talbot Heppenstall, Jr. | 1 | 2 |
| Ray Scott | 1 | 2 |
| Michael Fulton | 1 | 2 |
| Daniel Riskin | 1 | 1 |
| Alexander Ledebev | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.